NEW YORK (GenomeWeb) – BG Medicine's stock was down as much as 43 percent in morning trading on the OTC market following the company's announcement today that it has withdrawn its 510(k) premarket notification with the US Food and Drug Administration for an expanded indication of its BGM Galectin-3 test.

BG had hoped to obtain 510(k) clearance for use of the test in assessing the near-term risk of fatal cardiovascular events in older adults with no prior history of cardiovascular disease, cerebrovascular disease, or vascular disease.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.

Oct
10
Sponsored by
PerkinElmer

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.